Dermatologic Therapy

Papers
(The H4-Index of Dermatologic Therapy is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Issue Information83
Exploring and expanding frontiers in dermatology: Indigenous African dermatology73
Cryptococcal meningitis associated with interleukin‐17 inhibitor use for psoriasis67
52
The case of granuloma annulare associated with SARS‐CoV ‐2 infection49
Reply to “A case of symmetrical drug‐related intertriginous and flexural exanthema‐like eruption associated with Pfizer COVID ‐19 vaccination” by Manaa et al.44
Two birds with one stone: Successful treatment with methotrexate in a patient with generalized eruptive keratoacanthoma of Grzybowski and rheumatoid arthritis42
Fat herniation over striae distansea in focal dermal hypoplasia treated with 2940 nm Er: YAG Laser41
Cutaneous lupus erythematosus variants responsive to J anus kinase inhibition40
Microneedle fractional radiofrequency for atrophic acne scars: In vivo evaluation of results by 3D analysis and reflectance confocal microscopy40
Case report: Pyogenic granuloma—just salt, a simple and pain‐free treatment40
Epidemiology, clinical presentation, and management of pemphigoid nodularis: An update from Iran39
Switch from ustekinumab to guselkumab in patients with psoriasis in real clinical practice using the “minimal disease activity” parameter39
Ulcerative injection site reaction after third COVID ‐19 vaccine dose with mRNA ‐127338
Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis36
Tofacitinib in resistant chronic actinic dermatitis: A case series36
New‐onset systemic lupus erythematosus after ChAdOX1 nCoV‐19 and alopecia areata after BNT162b2 vaccination against SARS‐CoV‐236
Seroconversion after anti‐SARS‐CoV ‐2 mRNA vaccinations among moderate‐to‐severe psoriatic patients receiving systemic biologicals36
COVID ‐19 vaccine‐induced urticarial vasculitis35
Topical Timolol for ingrown nail post‐avulsion refractory wound35
Psoriasiform dermatitis induced by dupilumab successfully treated with upadacitinib34
Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients34
Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis33
Dapsone in hidradenitis suppurativa: A case series of 56 patients31
Ultraviolet A Combined with Narrow‐Band Ultraviolet B is an Effective Treatment Modality for Early Folliculotropic Mycosis Fungoides and Early Mycosis Fungoides Refractory to Narrow‐Band Ultraviolet B30
Comparison of Green‐Synthesized Silver Nanoparticle Shampoo Created by Moringa and Bergamot Extraction Versus 2% Ketoconazole Shampoo for Scalp Seborrheic Dermatitis: A Prospective, Randomized, Double30
Macrophage Migration Inhibitory Factor and Gene Polymorphism (rs755622G>C) in Unstable Vitiligo Patients30
Real‐World Guselkumab Response and Drug Survival in Australian Patients With Psoriasis: Results From the Australasian Psoriasis Registry30
Long‐term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified‐release capsules once daily29
Tofacitinib for the Treatment of Refractory Progressive Vitiligo: A Retrospective Case Series29
29
29
Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication29
0.19751381874084